Subscribe
Jo Panuwat D / Shutterstock.com
24 September 2024NewsAmericasLiz Hockley

Court denies Regeneron bid to halt copy of blockbuster eye drug

Biotech’s motion for preliminary injunction to prevent Eylea biosimilar rejected I Regeneron has filed multiple suits over rivals’ copies of aflibercept.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.


Editor's picks

Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025

Editor's picks

Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025

More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

More on this story

Americas
Regeneron targets almost 50 patents in suit against Sandoz
29 August 2024   Regeneron accused the Swiss pharma company of infringing a slew of patents related to Eylea and violating the BPCIA | Suit alleges that Sandoz failed to provide critical information during the approval process for its newly FDA-approved biosimilar | Sandoz “forced” Regeneron to guess which patents might be infringed.
Big Pharma
Regeneron sues Amgen over biosimilar version of blockbuster eye drug
16 January 2024   US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval.

More features

Fed Circ: Generic doesn’t infringe Metacel MS drug
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
Strategic IP protection for biotech-related GenAI
South Korean firm sues in UK over CRISPR/Cas9 blood disorder drug
In vivo cell therapy: A world beyond ex vivo engineering
Patent litigator with biotech and medical device background joins Sterlington
Resilience and the power of brands: Elisabeth Stewart Bradley on 9/11, inclusion and the INTA presidency